Image 1_A COP1-HY5-ABI5 module regulates ABA-mediated post-germination developmental arrest.pdf di Deeksha Singh (11009626)

Soggetti:

<b>The Dynamics of Sustainable Supply Chains: An Evolutionary Game of Leadership, AI Ethics, and Workforce Empowerment</b> di Rui Du (22668368)

Soggetti:

2D–shear-wave elastography example: non-MAFLD CKD case (male, 54 years). di Zienab M. Saad (22676502)

Soggetti:

2D–shear-wave elastography example: MAFLD + CKD case (male, 65 years). di Zienab M. Saad (22676502)

Soggetti:

eGFR in the study participants. di Zienab M. Saad (22676502)

Soggetti:

Demographic and Clinical Characteristics of Study Participants. di Zienab M. Saad (22676502)

Soggetti:

Stratification of Liver Stiffness according to eGFR in the MAFLD group. di Zienab M. Saad (22676502)

Soggetti:

Medication-inclusive multivariable logistic regression for MAFLD. di Zienab M. Saad (22676502)

Soggetti:

Receiver operating characteristic (ROC) curve analysis comparing the performance of non-invasive fibrosis scores in MAFLD patients. di Zienab M. Saad (22676502)

Soggetti:

Comparison of Non-invasive Liver Fibrosis Scores. di Zienab M. Saad (22676502)

Soggetti:

A. Violin plots showing eGFR distribution in MAFLD (red) vs. non-MAFLD (blue) groups. di Zienab M. Saad (22676502)

Soggetti:

Proposed pathophysiological crosstalk between MAFLD and CKD. di Zienab M. Saad (22676502)

Soggetti:

Liver Stiffness and Fibrosis Grading by MAFLD Status. di Zienab M. Saad (22676502)

Soggetti:

2D–shear-wave elastography example: MAFLD + CKD case (female, 57 years). di Zienab M. Saad (22676502)

Soggetti:

Grades of liver fibrosis in MAFLD group (grey) and non-MAFLD group (black). di Zienab M. Saad (22676502)

Soggetti:

Multivariable logistic regression models for MAFLD predictors. di Zienab M. Saad (22676502)

Soggetti:

Liver Fibrosis Characteristics by CKD Stage in MAFLD Patients (n = 64). di Zienab M. Saad (22676502)

Soggetti:

Supplementary Figure 5: Pathway analysis after treatment with KC and KCM serum in precursor cells di Sushil Kumar (20371917)

Soggetti:

Supplementary Figure 1: Activation of AD-MSCs and PSCs by Muc5ac di Sushil Kumar (20371917)

Soggetti:

Supplementary Figure 4: RNA-sequencing in the primary AD-MSCs, BM-MSCs, and PSCs after treatment with KC and KCM serum di Sushil Kumar (20371917)

Soggetti: